Gianna Link, MD
Payments from drug & device makers
Across 15 payments — averaging $82.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$914
- Otsuka America Pharmaceutical, Inc.$173
- Amgen$46
- Averitas Pharma Inc.$24
- Sanofi$24
- Neurocrine Biosciences, Inc.$23
- plus $33 from 2 others
What the payments were for
- Travel & lodging$56446%
- Food & beverage$65853%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 3 | $914 |
| Otsuka America Pharmaceutical, Inc. | 5 | $173 |
| Amgen | 2 | $46 |
| Averitas Pharma Inc. | 1 | $24 |
| Sanofi | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,237 in reported general payments places this provider in the 45th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naproxen | 664 | $23,314 |
| Ec-NaproxenNaproxen | 95 | $9,104 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 56 | $7,759 |
| Memantine Hcl ErMemantine Hcl | 148 | $6,634 |
| Lamotrigine ErLamotrigine | 55 | $6,373 |
| Tizanidine Hcl | 1,589 | $6,146 |
| Gabapentin | 750 | $5,594 |
| Donepezil Hcl | 926 | $4,896 |
| Memantine Hcl | 851 | $4,369 |
| Levetiracetam | 202 | $2,852 |
| Lamotrigine | 220 | $1,440 |
| Ropinirole ErRopinirole Hcl | 20 | $1,187 |
| Levetiracetam ErLevetiracetam | 39 | $1,147 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 50 | $909 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 41 | $847 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bronx
- Richard LiptonBronx$1.6M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.